文献速递癫痫神经重症与神经感染

儿童难治性惊厥性癫痫持续状态治疗时机与短期结局的关联

Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项多中心前瞻性队列研究纳入218例1月至21岁的难治性惊厥性癫痫持续状态患儿,比较一线苯二氮䓬类治疗在发作后<10分钟与≥10分钟(不及时)给药的短期结局。多因素分析显示,不及时治疗与死亡、需持续输注、惊厥持续时间更长及低血压更频繁独立相关。

要点

  • 儿童难治性惊厥性癫痫持续状态中,仅33.9%在发作后10分钟内接受一线苯二氮䓬类治疗。
  • 一线苯二氮䓬类治疗延迟≥10分钟与死亡风险增高独立相关(AOR 11.0)。
  • 延迟治疗还与需持续输注、惊厥持续时间延长和低血压更频繁相关。

核心结论

  • 在儿童难治性惊厥性癫痫持续状态中,一线苯二氮䓬类治疗不及时(≥10分钟)与死亡、需持续输注、惊厥持续时间更长和低血压更频繁独立相关。

研究设计与样本

  • 多中心、观察性、前瞻性队列研究,纳入美国11家三级医院在2011年6月1日至2016年7月7日期间的218例患儿。
  • 纳入年龄1月至21岁、至少接受2种抗癫痫发作药物后仍未停止的难治性惊厥性癫痫持续状态患者。
  • 按首次一线苯二氮䓬类治疗时间分为<10分钟组和≥10分钟(不及时)组。

主要发现

  • 218例中男性116例(53.2%),中位年龄4.0岁(IQR 1.2-9.6)。
  • 139例(63.8%)的难治性惊厥性癫痫持续状态始于院前。

临床怎么用

  • 对儿童惊厥性癫痫持续状态应尽早给予一线苯二氮䓬类治疗,尽量在发作后10分钟内启动。
  • 治疗延迟不仅增加死亡风险,还增加持续输注需求、惊厥持续时间和低血压风险。

局限性

  • 观察性设计不能完全排除混杂,死亡分析中95% CI上限为∞提示样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment delay for seizures can lead to longer seizure duration. Whether treatment delay is associated with major adverse outcomes, such as death, remains unknown. OBJECTIVE: To evaluate whether untimely first-line benzodiazepine treatment is associated with unfavorable short-term outcomes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, observational, prospective cohort study included 218 pediatric patients admitted between June 1, 2011, and July 7, 2016, into the 11 tertiary hospitals in the United States within the Pediatric Status Epilepticus Research Group. Patients, ranging in age from 1 month to 21 years, with refractory convulsive status epilepticus (RCSE) that did not stop after the administration of at least 2 antiseizure medications were included. Patients were divided into 2 cohorts: those who received the first-line benzodiazepine treatment in less than 10 minutes and those who received it 10 or more minutes after seizure onset (untimely). Data were collected and analyzed from June 1, 2011, to July 7, 2016. MAIN OUTCOMES AND MEASURES: The primary outcome was death during the related hospital admission. The secondary outcome was the need for continuous infusion for seizure termination. Multivariate analysis of mortality controlled for structural cause, febrile RCSE, age, and previous neurological history (including previous RCSE events). Use of continuous infusions was additionally adjusted for generalized RCSE, continuous RCSE, and 5 or more administrations of antiseizure medication. RESULTS: A total of 218 patients were included, among whom 116 (53.2%) were male and the median (interquartile range) age was 4.0 (1.2-9.6) years. The RCSE started in the prehospital setting for 139 patients (63.8%). Seventy-four patients (33.9%) received their first-line benzodiazepine treatment in less than 10 minutes, and 144 (66.1%) received untimely first-line benzodiazepine treatment. Multivariate analysis showed that patients who received untimely first-line benzodiazepine treatment had higher odds of death (adjusted odds ratio [AOR], 11.0; 95% CI, 1.43 to ∞; P = .02), had greater odds of receiving continuous infusion (AOR, 1.8; 95% CI, 1.01-3.36; P = .047), had longer convulsive seizure duration (AOR, 2.6; 95% CI, 1.38-4.88; P = .003), and had more frequent hypotension (AOR 2.3; 95% CI, 1.16-4.63; P = .02). In addition, the timing of the first-line benzodiazepine treatment was correlated with the timing of the second-line (95% CI, 0.64-0.95; P < .001) and third-line antiseizure medications (95% CI, 0.25-0.78; P < .001). CONCLUSIONS AND RELEVANCE: Among pediatric patients with RCSE, an untimely first-line benzodiazepine treatment is independently associated with a higher frequency of death, use of continuous infusions, longer convulsion duration, and more frequent hypotension. Results of this study raise the question as to whether poor outcomes could, in part, be prevented by earlier administration of treatment.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Gaínza-Lein M, Sánchez Fernández I, Jackson M, et al. Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus. JAMA Neurol. 2018. PMID: 29356811. doi:10.1001/jamaneurol.2017.4382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。